lymphoid cells

[XNK Therapeutics AB] XNK Therapeutics AB announced that the first patient has been included in a Phase II clinical study to treat patients with multiple myeloma using XNK’s leading autologous natural killer cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa.

[Nature Communications] Researchers showed that systemic delivery of αCD40 induced hypofunctional T cells and impaired the response to immune checkpoint inhibitors in pre-clinical glioma models.

[Human Genomics] Scientists used the commercial Chromium platform to perform sc-ATAC-seq to measure chromatin accessibility in 11,611 single umbilical cord blood cells derived from one trisomy 18 syndrome patient and one healthy donor.

[Leukemia] Scientists review the relevance and complications of clonal hematopoiesis for the treatment of hematologic malignancies with cell therapeutic approaches.

[Molecular Therapy] IdeS cleavage of host IgG averted Fc-dependent phagocytosis and lysis, and the residual F(ab')2 fragments remained on the surface, providing cells with an inert shield from additional IgG deposition.

[Nature Communications] Researchers showed that in vitro treatment of cytotoxic T lymphocytes and CAR T cells with pentanoate and butyrate increases the function of mTOR as a central cellular metabolic sensor, and inhibits class I histone deacetylase activity.